After its $2B Gilead pact, Goldfinch Bio nabs a cool $100M series B

Still flying high from its major biobucks pact with Gilead Sciences, kidney disease biotech Goldfinch Bio has followed up with a $100 million funding round.

Based in Cambridge, Massachusetts, Goldfinch Bio aims to use a precision medicine approach to better treat kidney disease. Its pipeline is based on its Kidney Genome Atlas, a patient registry containing genomic, transcriptomic and proteomic data with thousands of anonymized clinical patient profiles.